Quest Diagnostics (DGX) said, for full year 2026, the company now expects adjusted diluted EPS in a range of $10.63 $10.83, revised from prior guidance range of $10.50 $10.70. Net revenues are now expected in a range of $11.78 billion to $11.90 billion, updated from prior outlook range of $11.70 billion to $11.82 billion.
For the first quarter, the company's bottom line totaled $252 million, or $2.24 per share. This compares with $220 million, or $1.94 per share, last year. Excluding items, Quest reported adjusted earnings of $281 million or $2.50 per share for the period. Revenue rose 9.1% to $2.89 billion from $2.65 billion last year.
In pre-market trading on NYSE, Quest shares are up 2.39 percent to $201.00.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.